Ainos (AIMD) Registration Filing summary

Company overview and business model

• Diversified healthcare company focused on point-of-care testing (POCT), low-dose interferon alpha therapeutics (VELDONA), and synthetic RNA-driven preventative medicine.

• Product pipeline includes commercial-stage VELDONA Pet supplements, clinical-stage VELDONA human therapeutics, and AI Nose-powered POCTs.

• Business model emphasizes capital efficiency through operations in Taiwan, outsourced manufacturing, and global distribution partnerships.

• Holds a portfolio of 55 issued patents and 15 pending applications, with a focus on VOC and POCT technologies.

• Employs 44 full-time staff, primarily in Taiwan, with plans to expand R&D, sales, and operations.

Financial performance and metrics

• Issued a $9 million convertible note to ASE Test, Inc. in May 2024, convertible at $4.50 per share, with a three-year term and 6% compound interest.

• Paid off outstanding notes to i2China Management Group ($42,000) and Ainos KY ($270,000) in 2024.

• Last reported sale price of common stock on December 19, 2024, was $0.4401 per share.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares; all proceeds go to selling stockholders.

• Issued 5,500,000 shares to TCNT for patent license, 500,000 shares reserved for ASE Test warrant exercise, and additional shares for employee awards and agreements.